الفهرس 
Introduction and aim of workOnly 14 pages are availabe for public view
 |  | from | 207 |  |  |
| | | from | 207 | | |
Abstract
The results of the present study revealed that:
Compared to STZ diabetic rats, abn-cbd;
• Had no effect on diabetes-evoked cardiac hypertrophy, or the associate impaired glycemic control (hyperglycemia and hypoinsulinemia).
• Alleviated the reductions in LV contractility (dP/dtmax) and relaxation (dP/dtmin) indices, and the increases in LVEDP and cardiac vagal dominance.
• Reversed myocardial oxidative stress by restoring circulating and cardiac NO and ADN levels and enhancing GPR18 expression and phosphorylation of Akt, ERK1/2 and eNOS in diabetic rats’ hearts.
Concurrent GPR18 blockade (O-1918) abrogated all favorable effects of abn-cbd in diabetic rats.
In conclusion, abn-cbd improves cardiovascular functions in diabetes via activation of the endocannabinoid receptor, GPR18, which is expressed in the myocardium. The signaling mechanisms that mediate the abn-cbd –evoked cardiovascular effects include activation of Akt and ERK1/2 signaling pathways as well as adiponectin mediated elevation of nitric oxide levels and reduction of oxidative stress. GPR18 can be considered as a viable molecular target for developing new therapeutics that simultaneously improves cardiac function in diabetes.